Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Buy Rating from HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 44.61% from the stock’s current price.

ENTA has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. JPMorgan Chase & Co. started coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They set an “overweight” rating and a $17.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Trading Up 2.4%

NASDAQ ENTA opened at $13.83 on Tuesday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The company has a market capitalization of $401.35 million, a PE ratio of -3.61 and a beta of 0.98. The stock has a 50-day simple moving average of $14.11 and a 200 day simple moving average of $11.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $18.62 million during the quarter, compared to analyst estimates of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. As a group, sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the sale, the insider directly owned 30,620 shares in the company, valued at $435,722.60. The trade was a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jay R. Luly sold 4,743 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the transaction, the chief executive officer owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 11,961 shares of company stock valued at $170,149 in the last 90 days. 11.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Commodore Capital LP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $9,576,000. Millennium Management LLC grew its stake in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 645,791 shares of the biotechnology company’s stock valued at $10,187,000 after buying an additional 152,597 shares in the last quarter. Finally, Man Group plc acquired a new position in Enanta Pharmaceuticals during the third quarter worth $481,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.